Spots Global Cancer Trial Database for castration levels of testosterone
Every month we try and update this database with for castration levels of testosterone cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | NCT02966587 | Castration Leve... Hormone-Resista... Microsatellite ... | Durvalumab Laboratory Biom... | 18 Years - | University of Washington | |
| 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | NCT03805594 | Castration Leve... Castration-Resi... Metastatic Pros... Prostate Adenoc... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Lutetium Lu 177... Pembrolizumab | 18 Years - | University of California, San Francisco | |
| CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT01881867 | Castration Leve... Castration-Resi... Metastatic Pros... Stage IV Prosta... | Glycosylated Re... Laboratory Biom... | 18 Years - | Fred Hutchinson Cancer Center | |
| Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | NCT02966587 | Castration Leve... Hormone-Resista... Microsatellite ... | Durvalumab Laboratory Biom... | 18 Years - | University of Washington | |
| Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency | NCT03442556 | ATM Gene Mutati... BRCA1 Gene Muta... BRCA2 Gene Muta... Castration Leve... Castration-Resi... Homologous Reco... Prostate Carcin... PSA Level Great... PSA Progression Stage IV Prosta... | Carboplatin Docetaxel Laboratory Biom... Rucaparib Camsy... Rucaparib | 18 Years - | University of Washington | |
| Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide | NCT02228265 | Castration Leve... Castration-Resi... Prostate Adenoc... PSA Progression Recurrent Prost... Stage IV Prosta... | Cytology Specim... Enzalutamide Laboratory Biom... | - | OHSU Knight Cancer Institute | |
| Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer | NCT02215161 | Castration Leve... Hormone-Resista... Metastatic Pros... Prostate Carcin... PSA Progression Stage IV Prosta... | Selinexor | 18 Years - | University of California, San Francisco | |
| Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer | NCT03709550 | Castration Leve... Castration-Resi... Metastatic Pros... Prostate Carcin... PSA Level Great... PSA Progression Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Decitabine Enzalutamide | 18 Years - | Roswell Park Cancer Institute | |
| ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer | NCT03456804 | Castration Leve... Castration-Resi... Metastatic Pros... PSA Progression Stage IV Prosta... | ESK981 | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer | NCT03503344 | Castration Leve... Castration-Resi... PSA Progression Stage IV Prosta... | Apalutamide Stereotactic Bo... | 18 Years - | University of California, San Francisco | |
| Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer | NCT03709550 | Castration Leve... Castration-Resi... Metastatic Pros... Prostate Carcin... PSA Level Great... PSA Progression Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Decitabine Enzalutamide | 18 Years - | Roswell Park Cancer Institute | |
| Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer | NCT03406858 | Castration Leve... Castration-Resi... Prostate Carcin... PSA Progression Stage IV Prosta... | HER2Bi-Armed Ac... Laboratory Biom... Pembrolizumab | 19 Years - | Barbara Ann Karmanos Cancer Institute | |
| Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer | NCT03406858 | Castration Leve... Castration-Resi... Prostate Carcin... PSA Progression Stage IV Prosta... | HER2Bi-Armed Ac... Laboratory Biom... Pembrolizumab | 19 Years - | Barbara Ann Karmanos Cancer Institute | |
| Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer | NCT03503344 | Castration Leve... Castration-Resi... PSA Progression Stage IV Prosta... | Apalutamide Stereotactic Bo... | 18 Years - | University of California, San Francisco | |
| Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer | NCT03751436 | Castration Leve... Castration-Resi... Metastatic Pros... Metastatic Pros... Prostate Carcin... PSA Progression Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Enzalutamide Venetoclax | 18 Years - | Roswell Park Cancer Institute | |
| Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer | NCT03709550 | Castration Leve... Castration-Resi... Metastatic Pros... Prostate Carcin... PSA Level Great... PSA Progression Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Decitabine Enzalutamide | 18 Years - | Roswell Park Cancer Institute | |
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | NCT03678025 | Castration Leve... Metastatic Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Abiraterone Bicalutamide Degarelix Docetaxel Flutamide Goserelin Aceta... Histrelin Aceta... Leuprolide Acet... Nilutamide Orchiectomy Prednisone Quality-of-Life... Radiation Thera... Radical Prostat... Triptorelin | 18 Years - | SWOG Cancer Research Network | |
| Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer | NCT03751436 | Castration Leve... Castration-Resi... Metastatic Pros... Metastatic Pros... Prostate Carcin... PSA Progression Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Enzalutamide Venetoclax | 18 Years - | Roswell Park Cancer Institute | |
| ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer | NCT03456804 | Castration Leve... Castration-Resi... Metastatic Pros... PSA Progression Stage IV Prosta... | ESK981 | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer | NCT03456804 | Castration Leve... Castration-Resi... Metastatic Pros... PSA Progression Stage IV Prosta... | ESK981 | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | NCT03678025 | Castration Leve... Metastatic Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Abiraterone Bicalutamide Degarelix Docetaxel Flutamide Goserelin Aceta... Histrelin Aceta... Leuprolide Acet... Nilutamide Orchiectomy Prednisone Quality-of-Life... Radiation Thera... Radical Prostat... Triptorelin | 18 Years - | SWOG Cancer Research Network | |
| ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer | NCT03456804 | Castration Leve... Castration-Resi... Metastatic Pros... PSA Progression Stage IV Prosta... | ESK981 | 18 Years - | Barbara Ann Karmanos Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
